{"id":350,"date":"2014-03-29T10:41:09","date_gmt":"2014-03-29T10:41:09","guid":{"rendered":"https:\/\/blogs.bmj.com\/jnnp\/?p=350"},"modified":"2014-03-29T10:41:44","modified_gmt":"2014-03-29T10:41:44","slug":"are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","title":{"rendered":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS"},"content":{"rendered":"<p>Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective s<span class=\"irc_su\" dir=\"ltr\" style=\"text-align: left\">phingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm the therapeutic utility of ponesimod in RRMS,\u00a0 although choice is always good.\u00a0 Read more in JNNP:<br \/>\n<\/span><\/p>\n<p><!--[if gte mso 9]&gt;--><\/p>\n<p><!--[if gte mso 9]&gt;--><\/p>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\"><b><i><span style=\"font-size: 14.0pt;font-family: 'Times New Roman','serif'\">Olsson T, Boster A, Fern\u00e1ndez O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24659797\"><span style=\"color: #00006f;text-decoration: none\">Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.<\/span><\/a> J Neurol Neurosurg Psychiatry. 2014 Mar 21. doi: 10.1136\/jnnp-2013-307282. <\/span><\/i><\/b><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"irc_mut\" id=\"irc_mi\" style=\"margin-top: 0px\" alt=\"\" src=\"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg\" width=\"189\" height=\"189\" \/><\/p>\n<p>Ponesimod structure- Are the sphingosine wars beginning?<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective sphingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":160,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-350","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog\" \/>\n<meta property=\"og:description\" content=\"Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective sphingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/\" \/>\n<meta property=\"og:site_name\" content=\"JNNP blog\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-29T10:41:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-03-29T10:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg\" \/>\n<meta name=\"author\" content=\"Steve Vucic, Web Editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Vucic, Web Editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/\"},\"author\":{\"name\":\"Steve Vucic, Web Editor\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/5b9f797a427758da9d63182166e6458c\"},\"headline\":\"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS\",\"datePublished\":\"2014-03-29T10:41:09+00:00\",\"dateModified\":\"2014-03-29T10:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/\"},\"wordCount\":132,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/jpet.aspetjournals.org\\\/content\\\/337\\\/2\\\/547\\\/F1.large.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/\",\"name\":\"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/jpet.aspetjournals.org\\\/content\\\/337\\\/2\\\/547\\\/F1.large.jpg\",\"datePublished\":\"2014-03-29T10:41:09+00:00\",\"dateModified\":\"2014-03-29T10:41:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#primaryimage\",\"url\":\"http:\\\/\\\/jpet.aspetjournals.org\\\/content\\\/337\\\/2\\\/547\\\/F1.large.jpg\",\"contentUrl\":\"http:\\\/\\\/jpet.aspetjournals.org\\\/content\\\/337\\\/2\\\/547\\\/F1.large.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2014\\\/03\\\/29\\\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"name\":\"JNNP blog\",\"description\":\"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\",\"name\":\"JNNP blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"width\":427,\"height\":34,\"caption\":\"JNNP blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/5b9f797a427758da9d63182166e6458c\",\"name\":\"Steve Vucic, Web Editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g\",\"caption\":\"Steve Vucic, Web Editor\"},\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/author\\\/svucic\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","og_locale":"en_US","og_type":"article","og_title":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog","og_description":"Another oral agent has shown promise in a phase IIb trial for relapsing-remitting MS.\u00a0 Ponesimod, a selective sphingosine 1-Phosphate Receptor 1 Agonist, reduced disease burden and activity as assessed by MRI and clinical measures (annualized relapse rates).\u00a0\u00a0 Safety and tolerability\u00a0 were also assessed and proven to be good. \u00a0 Larger trials are required to confirm [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","og_site_name":"JNNP blog","article_published_time":"2014-03-29T10:41:09+00:00","article_modified_time":"2014-03-29T10:41:44+00:00","og_image":[{"url":"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg","type":"","width":"","height":""}],"author":"Steve Vucic, Web Editor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Steve Vucic, Web Editor","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/"},"author":{"name":"Steve Vucic, Web Editor","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/5b9f797a427758da9d63182166e6458c"},"headline":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS","datePublished":"2014-03-29T10:41:09+00:00","dateModified":"2014-03-29T10:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/"},"wordCount":132,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#primaryimage"},"thumbnailUrl":"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","url":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/","name":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS - JNNP blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#primaryimage"},"thumbnailUrl":"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg","datePublished":"2014-03-29T10:41:09+00:00","dateModified":"2014-03-29T10:41:44+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#primaryimage","url":"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg","contentUrl":"http:\/\/jpet.aspetjournals.org\/content\/337\/2\/547\/F1.large.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jnnp\/2014\/03\/29\/are-the-sphingosine-wars-beginning-ponesimod-promising-new-oral-agent-for-rrms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jnnp\/"},{"@type":"ListItem","position":2,"name":"Are the sphingosine wars beginning?: Ponesimod-Promising new oral agent for RRMS"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jnnp\/#website","url":"https:\/\/blogs.bmj.com\/jnnp\/","name":"JNNP blog","description":"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.","publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jnnp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization","name":"JNNP blog","url":"https:\/\/blogs.bmj.com\/jnnp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","width":427,"height":34,"caption":"JNNP blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/5b9f797a427758da9d63182166e6458c","name":"Steve Vucic, Web Editor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8e68076dae6fcffc1703a9f57f705b2f6f05335487da4d73145fa337d10c9b5a?s=96&d=mm&r=g","caption":"Steve Vucic, Web Editor"},"url":"https:\/\/blogs.bmj.com\/jnnp\/author\/svucic\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/160"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=350"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/350\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}